X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
DISC-1459 (bitopertin) is an investigational, clinical-stage, orally-administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. It is being evaluated for the treatment of erythropoietic protoporphyria.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
DISC-1459 (bitopertin) is an investigational, clinical-stage, orally-administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis, which is investigated for the treatment of diamond-blackfan anemia.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
The proceeds will fund research and clinical development of Disc's candidates including, DISC-1459 (bitopertin), a first-in-class, oral small molecule inhibitor of glycine transporter 1, to treat erythropoietic porphyrias, a rare, genetically-driven hematologic diseases.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $157.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
Details:
The proceeds will fund research and clinical development of Disc's candidates including, DISC-1459 (bitopertin), a first-in-class, oral small molecule inhibitor of glycine transporter 1, to treat erythropoietic porphyrias, a rare, genetically-driven hematologic diseases.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $137.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 13, 2023
Details:
The proceeds will fund research and clinical development of Disc's candidates including, DISC-1459 (bitopertin), a first-in-class, oral small molecule inhibitor of glycine transporter 1, to treat erythropoietic porphyrias, a rare, genetically-driven hematologic diseases.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 12, 2023
Details:
The collaboration will evaluate DISC-1459 (bitopertin), an orally administered inhibitor of GlyT1 that is designed to modulate heme biosynthesis, in a phase 2 clinical study of patients with Diamond-Blackfan anemia (DBA).
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: DISC-1459
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 21, 2023
Details:
The investment will primarily support development of Disc’s clinical-stage pipeline including DISC-1459 (bitopertin), a first-in-class, investigational, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $62.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 14, 2023
Details:
Disc Medicine (bitopertin) is an oral, selective inhibitor of glycine transporter 1. is developing bitopertin as the potentially first disease-modifying therapy to treat erythropoietic porphyrias – a family of rare, genetic disorders caused by dysregulated heme synthesis.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gemini Therapeutics
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Merger December 29, 2022
Details:
DISC-1459 (bitopertin) is an investigational oral, selective inhibitor of glycine transporter 1 designed to modulate heme biosynthesis, and has the potential to reduce accumulation of protoporphyrin IX, causing disease pathology in EPP patients, as per the preclinical studies.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
DISC-1459 (bitopertin) is an oral, selective inhibitor of GlyT1 designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX (PPIX), the toxic metabolite that causes disease pathology in EPP patients.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
The proceeds of the financing will be used to advance the development of Disc's hematology pipeline of therapeutic candidates. This includes conducting a phase 2 study of its lead program bitopertin, an oral, clinical-stage GlyT1 inhibitor.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: RO4917838
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 02, 2021
Details:
Under the terms of the agreement, Disc Medicine will obtain exclusive, global rights to and be responsible for all development, manufacturing, and commercialization of bitopertin and related back up compounds.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: RO4917838
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Disc medicine
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
